Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a 15-Minute chat at a testing site boost COVID-19 vaccination?

NCT ID NCT04939506

Completed Prevention Sponsor: Xavier University of Louisiana. Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests whether a brief vaccine education session given to unvaccinated adults when they come for COVID-19 testing can increase the number of people who get vaccinated. The education includes a 15-minute counseling session, printed materials, and a referral to a vaccine website. The trial focuses on vulnerable communities in southeastern Louisiana and tracks whether participants complete their COVID-19 vaccine series within 9 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a rapid vaccine education model delivered at the point of COVID-19 testing
What this could lead to
If effective, this approach could provide a simple, scalable way to boost vaccine uptake in communities that are hesitant or hard to reach.
What could go wrong
This is a small, single-region study, so results may not apply elsewhere. Education alone may not overcome deep-seated vaccine hesitancy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Vaccination Hesitancy Vaccination Refusal COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19 VACCINE HESITANCY VACCINE REFUSAL

Contacts and locations

Locations

  • Xavier University of Louisiana

    New Orleans, Louisiana, 70125, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.